Publications

Epstein L, Weiner AC, Verma A, Saeidi M, Carnevale J, Marson A, Engelhardt BE. Segmentation-free analysis of live-cell imaging data reveals how T cell modifications influence cancer cell aggregation dynamics. Scientific Reports. 2026. PMID: 42380368

Silverstein JF, Huppert LA, Schwede M, Goglin S, Johnson TP, Babik JM, Brondfield S. Optimizing a Hematology/Oncology Curriculum for Internal Medicine Residents: A Two-Institution Modified Delphi Study. Journal of cancer education : the official journal of the American Association for Cancer Education. 2026. PMID: 42380386

Reyes KR, Zhu R, Herberts C, Dutta P, Wray A, Mitchell B, Balkhi SS, Zhu X, Chu CE, Porten SP, Friedlander TW, Chou J, Seyedin SN, Sharma S, Malhotra M, ElNaggar AC, Liu MC, Ayanambakkam A, Koshkin VS. Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab. European urology oncology. 2026. PMID: 42379901

Faramand RG, Zhang A, Roloff GW, Aldoss I, Advani AS, Battiwalla M, Boccucci J, Byrd K, Cassaday RD, Connor M, Dykes KC, Hilal T, Kopmar NE, Kota VK, Lee CJ, Leonard JT, Lill GR, Lin C, Logan AC, Majhail NS, Malik SA, McCauley R, Moore J, Mountjoy L, O'Connor T, O'Dwyer KM, Bobillo SO, Oliai CH, Othman T, Ramakrishnan A, Sandhu K, Schwartz M, Shaughnessy P, Srinagesh HK, Sutherland KC, Tan V, Tsai SB, Ulrickson M, Wang ES, Yaghmour G, Frey NV, Shah BD, Muffly LS. Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia: Results from the Real-World Outcomes Collaborative of Chimeric Antigen Receptor T in Adult Acute Lymphoblasti Transplantation and cellular therapy. 2026. PMID: 42364734

Rugo HS, Cescon DW, Schmid P, Nowecki Z, Im SA, Md Yusof M, Gallardo C, Iwata H, Lipatov O, Cruz F, Barrios CH, Hegg R, Loi S, Gion M, Otero MT, Árkosy P, Tarnawski R, Yao L, Mejia J, Pan W, Cortés J. Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events. NPJ breast cancer. 2026. PMID: 42362563

Mohanty A, Stead AE, Telep LE, Singer AW, Curteis T, Zolotor A, Frenette C, Khoshabafard D, Hammond K, McQuaid T, Kelley RK. Hepatocellular carcinoma risk reduction associated with antiviral treatment in patients with noncirrhotic chronic hepatitis B: a systematic literature review and comparative meta-analysis. BMC gastroenterology. 2026. PMID: 42363070

Othman T, Roloff GW, Miller K, Zhang A, Sutherland KC, Faramand RG, Hill LC, Muhsen IN, Jeyakumar N, Ladha A, Sasine JP, Lin C, Kopmar NE, Tsai SB, O'Connor TE, Hilal T, Solh MM, Guzowski C, Tan V, Majhail NS, Battiwalla M, Malik SA, Mathews J, Shaughnessy PJ, Mountjoy L, Dykes KC, Logan AC, Schwartz MS, Connor MP, Wang J, Vasu S, Kumaran M, Hoeg RT, Tracy SI, Yalniz FF, Yaghmour G, Pullarkat VA, Cassaday RD, Leonard JT, Shah BD, Frey NV, Muffly LS, Aldoss I. Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL. Blood advances. 2026. PMID: 42349018

Desai SH, Geyer SM, Pederson L, Spinner MA, Bachanova V, Evens AM, Goyal G, Kahl B, Dorritie K, Azzi J, Kenkre VP, Chang C, Fusco B, Sumransub N, Hatic H, Saba R, Ibrahim U, Harris EI, Shah H, Wagner-Johnston N, Jagadeesh D, Blum KA, Diefenbach C, Iyengar S, Rappazzo KC, Baidoun F, Choi Y, Advani RH, Mocikova H, Sykorova A, Michalka J, Prochazka V, Micallef IN. Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma. Blood cancer journal. 2026. PMID: 42343091

Aggarwal R, Ruff CT, Palazzolo MG, Büttner FC, Pieper K, Eikelboom J, Patel M, Granger CB, Wallentin L, Hijazi Z, Virdone S, Zimetbaum P, Secemsky EA, Kakkar AK, Giugliano RP, Yeh RW. DOAC score among patients receiving Vitamin K antagonists. American heart journal. 2026. PMID: 42336120

Deroy C, Islam MN, Goldhammer N, Jiang L, Rosenbluth JM, Herr AE. AutoBlot: deterministic single-cell western blotting reveals proteomic diversity in rare cell populations. bioRxiv : the preprint server for biology. 2026. PMID: 42395434

Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Curigliano G, Brufsky A. Comparison of survival outcomes for people with HR+/HER2- metastatic breast cancer who received palbociclib, ribociclib, or abemaciclib with an aromatase inhibitor: a plain language summary. Future oncology (London, England). 2026. PMID: 42324670

Rugo HS, Liu X, Li B, McRoy L, Chen C, Makari D, Layman RM, Brufsky A. Treatment outcomes with palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer who also have cardiovascular diseases: a plain language summary. Future oncology (London, England). 2026. PMID: 42324685

Saglam A, Kumar J, Van Ziffle J, Mukherjee S, Singh K, Ruiz-Cordero R, Morrison M, Huang F, Cagdas D, Ozogul E, Uner A, Ohgami RS. Study of inborn errors of immunity associated lymphoid proliferations identifies association of presence of somatic variations with large cell morphology, copy number alterations in TNFAIP3 and heterozygous variants in EMSY. Virchows Archiv : an international journal of pathology. 2026. PMID: 42322427

Trudeau J, Thati N, Ng DQ, Chavez-Iglesias E, Olshen AB, Dhruva A, Chan JW, Chan RJ, Chan A, Kober KM. Distinct neuronal, proliferative, and secretory pathways are perturbed in cancer survivors with depressive symptoms. medRxiv : the preprint server for health sciences. 2026. PMID: 42369470

Truong AA, Ho S, Apostolova MKI, Lee RH, Wu X, Kang H, El-Sayed IH, George JR, Heaton CM, Likhterov I, Xu MJ, Spitzer MH, Ha PK, Algazi AP, Wai KC. Metastatic Lymph Node Status Is Associated With Progression-Free Survival in Oral Cavity Squamous Cell Carcinoma Treated With Pembrolizumab. Head & neck. 2026. PMID: 42315475

Schinke C, Touzeau C, Oriol A, Mateos MV, Stevens D, Rasche L, Moreau P, San-Miguel J, Rodríguez-Otero P, Kato K, Bathija S, Katz EG, Masterson T, Tomlinson C, Chari A. A plain language summary describing how talquetamab affects the way people with multiple myeloma feel and function in the MonumenTAL-1 study. Future oncology (London, England). 2026. PMID: 42299486

Lombardi P, Ramon-Gil E, Raja RQ, Brunetti L, Manfredi GF, Zhou Z, Merces G, Cappuyns S, Fulgenzi CAM, D'Alessio A, Torkpour A, Celsa C, Stefanini B, Yang H, Crowley F, Marron TU, Saeed A, Pinter M, Scheiner B, Huang YH, Lee PC, Nishida N, Po-Ting Lin R, Dalbeni A, Vivaldi C, Masi G, Rohlen N, von Felden J, Kaseb A, Galle PR, Kudo M, Hsu WF, Rimassa L, Parisi A, Kelley RK, Toyoda H, Pirisi M, Jabar F, Rakaee M, Cabibbo G, Cammà C, Piscaglia F, Hwang S, Shin DJ, Li M, Dekervel J, Guerra N, Meyer T, Reeves HL, Bengsch B, Daniele G, Mann DA, Chon HJ, Leslie J, Pinato DJ. A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma. Journal of hepatology. 2026. PMID: 42297215

Olando YA, Onyango RM, Bukusi EA, Brown J, Ongeri L, Shade SB, Vijayaraghavan M, Odhiambo FA, Osongo CO, Cohen CR, Magati P, Kwena Z, Rota G, Chatterjee P, Osula CA, Ouner JJ, Bialous SS. Change in self-reported tobacco cessation support practices among HIV providers in Kisumu, Kenya: a pre-post evaluation of a web-based training programme nested within the IN-ToUCH cluster randomised trial. BMJ public health. 2026. PMID: 42344040

Kimambo AH, Vuhahula E, Mmbaga EJ, Baraka BM, Malango A, Illonga Z, Mushi BP, Kitosho B, Van Loon K, Ng DL. Contextual Barriers and Facilitators to Implementing Ultrasound-Guided Fine-Needle Aspiration and Rapid Onsite Evaluation in a Resource-Limited Setting. JCO global oncology. 2026. PMID: 42269133

Llovet JM, Mauro E, Rimassa L, Mazzaferro V, Pinter M, Kelley RK, Chan SL, Kulik L, Pillai A, Roberts L, Sangro B, Casanovas T, Kaplan DE, Vogel A, Yarchoan M, Finn RS, Meyer T, Singal AG. Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement. Nature reviews. Clinical oncology. 2026. PMID: 42270817